Dataset Information


ML29755 RNA-seq data

ABSTRACT: Programmed death-ligand 1 (PD-L1) expression has been associated with response to PD-1/PD-L1 inhibition, but responses are also seen in patients with PD-L1 negative tumors when assessed immunohistochemically (IHC) with various antibodies. To help elucidate these findings, we performed a positron emission tomography (PET) imaging study in human with the anti-PD-L1 antibody atezolizumab labeled with Zirconium-89 (89Zr) prior to treatment with atezolizumab to assess normal tissue distribution and evaluate tumor tracer uptake. Additionally, to help explain why some patients respond to checkpoint inhibitors despite low or absent PD-L1 expression, we compared PD-L1 expression and immune phenotypes based on both CD8 IHC and RNA sequencing of post-tracer biopsies to tumor tracer uptake (SUVmax). Overall design: In this trial, 22 patients completed the full imaging series of up to 4 PET scans and were subsequently treated with atezolizumab monotherapy until progressive disease (PD) from which 11 post-tracer tumor biopsies were available for RNA sequencing, which are available here.

INSTRUMENT(S): Illumina HiSeq 2500 (Homo sapiens)

SUBMITTER: Craig Cummings 

PROVIDER: GSE115594 | GEO | 2018-06-12


Dataset's files

Action DRS
GSE115594_RAW.tar Raw
filelist.txt Txt
Items per page:
1 - 2 of 2
altmetric image


Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of patients with several tumor types, but predicting patient benefit using approved diagnostics is inexact, as some patients with PD-L1-negative tumors also show clinical benefit<sup>1,2</sup>. Moreover, all biopsy-based tests are subject to the errors and limitations of invasive tissue collection<sup>3-11</sup>. Preclinical studies of positron-emission tomography (PET) imaging with antibodies to PD-L1 sugges  ...[more]

Similar Datasets

2018-01-01 | S-EPMC6220188 | BioStudies
2020-01-01 | S-EPMC7293073 | BioStudies
2017-01-01 | S-EPMC5642894 | BioStudies
2017-01-01 | S-EPMC5543907 | BioStudies
2020-01-01 | S-EPMC7101303 | BioStudies
2020-01-01 | S-EPMC7692040 | BioStudies
2020-01-01 | S-EPMC6954462 | BioStudies
1000-01-01 | S-EPMC5373501 | BioStudies
2019-01-01 | S-EPMC6521689 | BioStudies
2016-01-01 | S-EPMC4955062 | BioStudies